Gossamer could put pressure on Merck

Following the hit in the pivotal Stellar trial, sotatercept is on course to become the first disease-modifying therapy for pulmonary arterial hypertension. At least, that’s what its developer Merck says – but there are several more projects in development for this rare disease that might give Merck a run for its money.